Intercept Pharmaceuticals Company Profile (NASDAQ:ICPT)

About Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals logoIntercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ICPT
  • CUSIP: 45845P10
  • Web:
  • Market Cap: $3.22 billion
  • Outstanding Shares: 25,009,000
Average Prices:
  • 50 Day Moving Avg: $123.91
  • 200 Day Moving Avg: $117.53
  • 52 Week Range: $96.63 - $177.93
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.21
  • P/E Growth: -1.28
Sales & Book Value:
  • Annual Revenue: $45.55 million
  • Price / Sales: 70.73
  • Book Value: $9.60 per share
  • Price / Book: 13.42
  • EBIDTA: ($355,150,000.00)
  • Net Margins: -825.58%
  • Return on Equity: -116.30%
  • Return on Assets: -50.83%
  • Debt-to-Equity Ratio: 1.44%
  • Current Ratio: 8.74%
  • Quick Ratio: 8.74%
  • Average Volume: 354,416 shs.
  • Beta: -1.99
  • Short Ratio: 13.25
Frequently Asked Questions for Intercept Pharmaceuticals (NASDAQ:ICPT)

What is Intercept Pharmaceuticals' stock symbol?

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

How were Intercept Pharmaceuticals' earnings last quarter?

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) released its quarterly earnings results on Thursday, May, 4th. The company reported ($3.61) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($4.27) by $0.66. The business earned $21 million during the quarter, compared to analysts' expectations of $15.88 million. Intercept Pharmaceuticals had a negative return on equity of 116.30% and a negative net margin of 825.58%. The company's quarterly revenue was up 4566.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($5.17) earnings per share. View Intercept Pharmaceuticals' Earnings History.

Where is Intercept Pharmaceuticals' stock going? Where will Intercept Pharmaceuticals' stock price be in 2017?

16 equities research analysts have issued 1 year price targets for Intercept Pharmaceuticals' stock. Their predictions range from $60.00 to $350.00. On average, they anticipate Intercept Pharmaceuticals' stock price to reach $203.00 in the next year. View Analyst Ratings for Intercept Pharmaceuticals.

What are analysts saying about Intercept Pharmaceuticals stock?

Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Intercept received a boost with the approval of Ocaliva in 2016 and the initial uptake of the same has been encouraging. The drug’s sale is expected to pick up further in 2017. The PBC market holds strong potential.  We are also encouraged by Intercept’s efforts to develop the drug for additional indications. A potential label expansion of the drug will further boost sales. The company does not expect much contribution from international markets in 2017 and most of it will be loaded in the second half as it works to obtain reimbursements in various European countries. However, expenses are expected to continue to rise as the company invests in commercial activities related to Ocaliva. We also remain concerned about the lack of other late-stage candidates in Intercept’s pipeline.  Moreover, the company’s share underperformed the industry in the last one year." (7/11/2017)
  • 2. Cowen and Company analysts commented, "We hosted a group investor lunch recently with ICPT management." (6/12/2017)
  • 3. BMO Capital Markets analysts commented, "We are raising our PT to $221 from $198 as we believe updated launch metrics suggest continued steady uptake of Ocaliva for PBC driven by greater physician awareness and more open access, supporting our above-consensus 2017 sales estimates. We believe the removal of the REGENERATE enrollment overhang could allow ICPT shares to trade up meaningfully on any signs of efficacy in PSC Ph2 as it remains a source of upside to our and Street estimates. We expect Ocaliva sales growth and development milestones to help ICPT shares recover." (2/24/2017)
  • 4. Wedbush analysts commented, "We believe several clinical catalysts later this year could provide upside to ICPT's current price. Q4/FY:16 Financials: Q4/FY:16 Ocaliva sales were $13.4MM/$18.2MM. Revenues of $13.8MM/$24.9MM also came in higher than consensus estimates of $8.96MM/$20.16MM. GAAP (loss) of $(4.84)/$16.74) came in lower than consensus estimates of $(3.68)/($15.63) on higher than expected SG&A expenses. We have incorporated Q4/FY:16 financials and updated our model based on 2017 guidance. ICPT ended 2016 with cash balance of $689.4MM. Progress on the Ocaliva launch. ICPT appears to be making significant progress with reimbursement, with the time to filled-prescription now at three weeks." (2/24/2017)
  • 5. Needham & Company LLC analysts commented, "Intercept reported 4Q16 financial results today. Ocaliva sales were $13.4M, compared to our $9.0M and consensus $7.8M est. Mgmt cited better than expected gross:net. No sales guidance was issued, as expected, although mgmt indicated 1Q17 sales will only be modestly above 4Q16, w/ expectations for gross:net to worsen. As a reminder, drug was launched in Jun 2016 for treatment of PBC. Ocaliva launch is progressing well, but we believe this is already factored in stock. Mgmt recently negotiated changes to Phase 3 REGENERATE NASH trial design, allowing for smaller pt population. We expect a favorable outcome, but note results will still not be available until 1H19." (2/23/2017)

Who are some of Intercept Pharmaceuticals' key competitors?

Who are Intercept Pharmaceuticals' key executives?

Intercept Pharmaceuticals' management team includes the folowing people:

  • Paolo Fundaro, Independent Chairman of the Board
  • Mark Pruzanski M.D., President, Chief Executive Officer, Director
  • Sandip S. Kapadia, Chief Financial Officer, Treasurer
  • Lisa Bright, President, International
  • Jerome Benedict Durso, Chief Operating Officer
  • David Ford, Chief Human Resource Officer
  • David M. Shapiro M.D., Chief Medical Officer, Executive Vice President - Development
  • Richard Kim, Senior Vice President, Commercial U.S.
  • Rachel L. McMinn Ph.D., Chief Business and Strategy Officer
  • Srinivas Akkaraju M.D. Ph.D., Independent Director

Who owns Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Bank of Montreal Can (0.10%), ING Groep NV (0.04%), Fox Run Management L.L.C. (0.02%), Rothschild Investment Corp IL (0.02%), Public Employees Retirement Association of Colorado (0.02%) and Creative Planning (0.01%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Klaus R Dr Veitinger, Lisa Bright, Mark Pruzanski, Nicole Williams, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.

Who sold Intercept Pharmaceuticals stock? Who is selling Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Creative Planning and Bank of Montreal Can. Company insiders that have sold Intercept Pharmaceuticals stock in the last year include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.

Who bought Intercept Pharmaceuticals stock? Who is buying Intercept Pharmaceuticals stock?

Intercept Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including ING Groep NV, Fox Run Management L.L.C., Aperio Group LLC and Public Employees Retirement Association of Colorado. View Insider Buying and Selling for Intercept Pharmaceuticals.

How do I buy Intercept Pharmaceuticals stock?

Shares of Intercept Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Intercept Pharmaceuticals' stock price today?

One share of Intercept Pharmaceuticals stock can currently be purchased for approximately $128.82.

MarketBeat Community Rating for Intercept Pharmaceuticals (NASDAQ ICPT)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  614 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  860
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 4 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $203.00 (57.58% upside)

Analysts' Ratings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/10/2017Jefferies Group LLCInitiated CoverageBuy -> Buy$275.00HighView Rating Details
6/23/2017WedbushReiterated RatingOutperform$231.00MediumView Rating Details
6/12/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
6/3/2017Credit Suisse GroupSet Price TargetBuy$201.00MediumView Rating Details
5/5/2017BMO Capital MarketsReiterated RatingOutperform$221.00 -> $223.00LowView Rating Details
5/5/2017LaidlawUpgradeSell -> Hold$115.00LowView Rating Details
5/4/2017Cantor FitzgeraldSet Price TargetSell$60.00LowView Rating Details
5/4/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$200.00LowView Rating Details
2/28/2017Citigroup Inc.Set Price TargetBuy$275.00 -> $240.00N/AView Rating Details
2/24/2017Leerink SwannLower Price TargetMarket Perform$116.00 -> $110.00N/AView Rating Details
2/23/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
2/16/2017Robert W. BairdReiterated RatingOutperform$332.00N/AView Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/AView Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyN/AView Rating Details
9/28/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
8/5/2016Morgan StanleyReiterated RatingSell$80.00N/AView Rating Details
6/1/2016Barclays PLCReiterated RatingBuy$200.00 -> $205.00N/AView Rating Details
5/31/2016Goldman Sachs Group, Inc. (The)Boost Price TargetNeutral$114.00 -> $128.00N/AView Rating Details
4/9/2016Bank of America CorporationReiterated RatingSell$144.00N/AView Rating Details
1/28/2016S&P Equity ResearchReiterated RatingAverage$100.60 -> $111.91N/AView Rating Details
8/7/2015Janney Montgomery ScottReiterated RatingBuyN/AView Rating Details
(Data available from 7/26/2015 forward)


Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Earnings by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Earnings History by Quarter for Intercept Pharmaceuticals (NASDAQ ICPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($4.27)($3.61)$15.88 million$21.00 millionViewListenView Earnings Details
2/23/2017Q416($3.74)($4.84)$8.96 million$13.00 millionViewN/AView Earnings Details
11/3/2016Q316($3.82)($3.59)$4.77 million$4.70 millionViewN/AView Earnings Details
8/4/2016Q216($3.69)($3.14)$1.72 million$5.52 millionViewN/AView Earnings Details
5/5/2016Q1($3.60)($3.33)$0.49 million$0.45 millionViewN/AView Earnings Details
2/23/2016Q415($3.15)($3.62)$0.43 million$0.45 millionViewListenView Earnings Details
11/9/2015Q315($2.74)($2.10)$0.42 million$0.45 millionViewN/AView Earnings Details
8/5/2015Q215($1.95)($1.99)$2.17 million$0.45 millionViewN/AView Earnings Details
5/11/2015Q115($1.75)($1.78)$1.70 million$1.70 millionViewListenView Earnings Details
3/2/2015Q414($1.53)($1.63)$0.42 million$0.04 millionViewN/AView Earnings Details
11/6/2014Q3($1.10)($1.69)$0.46 million$0.45 millionViewN/AView Earnings Details
8/11/2014Q214($1.10)$1.51$400.00 million$405.40 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.72)($1.59)$0.41 million$0.41 millionViewN/AView Earnings Details
3/14/2014Q4 13($0.70)($0.64)ViewN/AView Earnings Details
11/14/2013Q313($0.51)($1.65)$0.89 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.51)($0.79)$0.40 million$0.41 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)
2017 EPS Consensus Estimate: ($14.55)
2018 EPS Consensus Estimate: ($11.29)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($4.62)($3.39)($4.02)
Q2 20175($3.87)($3.28)($3.66)
Q3 20175($3.80)($2.91)($3.41)
Q4 20174($3.69)($2.88)($3.45)
Q1 20181($3.57)($3.57)($3.57)
Q2 20181($3.06)($3.06)($3.06)
Q3 20181($2.57)($2.57)($2.57)
Q4 20181($2.09)($2.09)($2.09)
(Data provided by Zacks Investment Research)


Dividend History for Intercept Pharmaceuticals (NASDAQ:ICPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 84.24%
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Insider Trades by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/20/2017Daniel G WelchDirectorSell217$126.76$27,506.92View SEC Filing  
7/14/2017Richard J KimSVPSell89$128.64$11,448.96View SEC Filing  
7/11/2017David ShapiroCMOSell553$124.01$68,577.53View SEC Filing  
7/3/2017David ShapiroCMOSell350$121.24$42,434.00View SEC Filing  
7/3/2017Lisa BrightInsiderSell394$121.33$47,804.02View SEC Filing  
7/3/2017Mark PruzanskiCEOSell1,434$121.78$174,632.52View SEC Filing  
7/3/2017Richard J KimSVPSell50$121.69$6,084.50View SEC Filing  
7/3/2017Sandip KapadiaCFOSell1,431$121.59$173,995.29View SEC Filing  
6/26/2017Mark PruzanskiCEOSell40,000$130.80$5,232,000.00View SEC Filing  
6/1/2017Lisa BrightInsiderSell698$110.73$77,289.54View SEC Filing  
5/25/2017Lisa BrightInsiderSell254$117.52$29,850.08View SEC Filing  
5/16/2017Lisa BrightInsiderSell113$119.74$13,530.62View SEC Filing  
5/2/2017Lisa BrightInsiderSell426$114.00$48,564.00View SEC Filing  
5/1/2017David ShapiroCMOSell1,117$112.18$125,305.06View SEC Filing  
5/1/2017Rachel McminnInsiderSell114$113.12$12,895.68View SEC Filing  
4/10/2017David ShapiroCMOSell558$108.51$60,548.58View SEC Filing  
4/3/2017David ShapiroCMOSell346$115.00$39,790.00View SEC Filing  
4/3/2017Lisa BrightInsiderSell389$115.00$44,735.00View SEC Filing  
4/3/2017Mark PruzanskiCEOSell1$115.00$115.00View SEC Filing  
2/27/2017Lisa BrightInsiderSell254$119.48$30,347.92View SEC Filing  
1/31/2017Lisa BrightInsiderSell134$108.96$14,600.64View SEC Filing  
1/9/2017David ShapiroCMOSell1,565$106.01$165,905.65View SEC Filing  
1/3/2017David ShapiroCMOSell988$103.92$102,672.96View SEC Filing  
1/3/2017Mark PruzanskiCEOSell2,802$103.92$291,183.84View SEC Filing  
1/3/2017Rachel McminnInsiderSell816$103.92$84,798.72View SEC Filing  
12/2/2016David ShapiroCMOSell1,350$99.75$134,662.50View SEC Filing  
11/25/2016Lisa BrightInsiderSell249$113.60$28,286.40View SEC Filing  
10/31/2016Rachel McminnInsiderSell129$123.82$15,972.78View SEC Filing  
10/10/2016David ShapiroCMOSell411$153.34$63,022.74View SEC Filing  
10/3/2016Barbara Gayle DuncanCAOSell147$163.20$23,990.40View SEC Filing  
10/3/2016David ShapiroCMOSell1,513$163.08$246,740.04View SEC Filing  
10/3/2016Lisa BrightInsiderSell155$163.20$25,296.00View SEC Filing  
10/3/2016Mark PruzanskiCEOSell705$163.20$115,056.00View SEC Filing  
9/26/2016David ShapiroCMOSell3,545$165.08$585,208.60View SEC Filing  
9/20/2016Mark PruzanskiCEOSell35,000$165.00$5,775,000.00View SEC Filing  
8/25/2016Lisa BrightInsiderSell246$159.00$39,114.00View SEC Filing  
8/1/2016Rachel McminnInsiderSell125$176.57$22,071.25View SEC Filing  
7/5/2016Barbara Gayle DuncanCAOSell146$145.11$21,186.06View SEC Filing  
7/5/2016David ShapiroCMOSell163$145.11$23,652.93View SEC Filing  
7/5/2016Lisa BrightInsiderSell155$145.11$22,492.05View SEC Filing  
7/5/2016Mark PruzanskiCEOSell714$145.11$103,608.54View SEC Filing  
5/25/2016Lisa BrightInsiderSell251$137.50$34,512.50View SEC Filing  
5/2/2016Rachel McminnInsiderSell130$147.49$19,173.70View SEC Filing  
4/4/2016Barbara Gayle DuncanCFOSell144$130.76$18,829.44View SEC Filing  
4/4/2016David ShapiroCMOSell165$130.76$21,575.40View SEC Filing  
4/4/2016Lisa BrightInsiderSell153$130.76$20,006.28View SEC Filing  
4/4/2016Mark PruzanskiCEOSell708$130.76$92,578.08View SEC Filing  
2/25/2016Lisa BrightInsiderSell241$115.22$27,768.02View SEC Filing  
2/1/2016Rachel McminnInsiderSell128$103.56$13,255.68View SEC Filing  
1/13/2016Lisa BrightinsiderSell728$125.52$91,378.56View SEC Filing  
1/4/2016Barbara Gayle DuncanCFOSell468$145.90$68,281.20View SEC Filing  
1/4/2016David ShapiroCMOSell533$145.90$77,764.70View SEC Filing  
1/4/2016Mark PruzanskiCEOSell2,126$145.90$310,183.40View SEC Filing  
1/4/2016Rachel McminnInsiderSell469$145.90$68,427.10View SEC Filing  
11/25/2015Lisa BrightInsiderSell1,150$182.96$210,404.00View SEC Filing  
11/16/2015David ShapiroCMOSell4,264$178.53$761,251.92View SEC Filing  
11/10/2015David ShapiroCMOSell3,500$204.15$714,525.00View SEC Filing  
11/10/2015Klaus R. Dr VeitingerDirectorSell1,000$198.25$198,250.00View SEC Filing  
11/2/2015Rachel McminnInsiderSell125$160.24$20,030.00View SEC Filing  
10/2/2015Barbara Gayle DuncanCFOSell1,054$163.17$171,981.18View SEC Filing  
10/2/2015David ShapiroCMOSell1,140$160.12$182,536.80View SEC Filing  
9/21/2015Nicole WilliamsDirectorSell973$194.82$189,559.86View SEC Filing  
9/15/2015David ShapiroCMOSell3,500$191.28$669,480.00View SEC Filing  
8/17/2015David ShapiroCMOSell4,272$209.37$894,428.64View SEC Filing  
7/20/2015Nicole WilliamsDirectorSell973$279.01$271,476.73View SEC Filing  
7/10/2015Mark PruzanskiCEOSell12,500$250.00$3,125,000.00View SEC Filing  
7/6/2015Luciano AdoriniInsiderSell4,067$579.93$2,358,575.31View SEC Filing  
7/1/2015Barbara Gayle DuncanCFOSell1,000$242.10$242,100.00View SEC Filing  
7/1/2015David ShapiroCMOSell3,781$238.66$902,373.46View SEC Filing  
6/22/2015Nicole WilliamsDirectorSell974$265.14$258,246.36View SEC Filing  
6/15/2015David ShapiroCMOSell3,500$241.58$845,530.00View SEC Filing  
6/8/2015Luciano AdoriniInsiderSell4,000$248.40$993,600.00View SEC Filing  
5/11/2015Klaus R Dr VeitingerDirectorSell391$279.07$109,116.37View SEC Filing  
5/6/2015Luciano AdoriniInsiderSell4,000$259.97$1,039,880.00View SEC Filing  
4/20/2015Nicole WilliamsDirectorSell974$278.50$271,259.00View SEC Filing  
4/6/2015Luciano AdoriniInsiderSell4,000$269.64$1,078,560.00View SEC Filing  
4/2/2015David ShapiroCMOSell3,459$275.25$952,089.75View SEC Filing  
3/26/2015Orbimed Advisors LlcDirectorSell157,200$286.75$45,077,100.00View SEC Filing  
3/25/2015Orbimed Advisors LlcDirectorSell207,800$274.41$57,022,398.00View SEC Filing  
3/24/2015Jonathan SilversteinDirectorSell45,600$272.00$12,403,200.00View SEC Filing  
3/23/2015Jonathan SilversteinDirectorSell159,400$275.18$43,863,692.00View SEC Filing  
3/16/2015David ShapiroCMOSell3,500$286.90$1,004,150.00View SEC Filing  
1/12/2015Klaus R Dr VeitingerDirectorSell233$150.01$34,952.33View SEC Filing  
1/5/2015Barbara Gayle DuncanCFOSell141$176.49$24,885.09View SEC Filing  
1/5/2015Daniel Paul ReganInsiderSell146$176.49$25,767.54View SEC Filing  
1/5/2015David ShapiroCMOSell664$172.63$114,626.32View SEC Filing  
1/5/2015Mark PruzanskiCEOSell461$176.49$81,361.89View SEC Filing  
1/2/2015Barbara Gayle DuncanCFOSell1,000$156.40$156,400.00View SEC Filing  
11/17/2014David ShapiroCMOSell4,790$158.82$760,747.80View SEC Filing  
11/12/2014Srinivas AkkarajuDirectorBuy2,000$167.19$334,380.00View SEC Filing  
11/10/2014Klaus R Dr VeitingerDirectorSell233$175.95$40,996.35View SEC Filing  
11/3/2014Mark PruzanskiCEOSell10,000$259.41$2,594,100.00View SEC Filing  
10/10/2014Klaus R Dr VeitingerDirectorSell391$223.65$87,447.15View SEC Filing  
10/2/2014David ShapiroCMOSell5,020$231.63$1,162,782.60View SEC Filing  
10/1/2014Barbara Gayle DuncanCFOSell1,000$233.12$233,120.00View SEC Filing  
10/1/2014David ShapiroCMOSell4,188$231.17$968,139.96View SEC Filing  
10/1/2014Mark PruzanskiCEOSell10,000$228.82$2,288,200.00View SEC Filing  
9/15/2014David ShapiroCMOSell4,000$281.19$1,124,760.00View SEC Filing  
9/10/2014Klaus R Dr VeitingerDirectorSell391$280.50$109,675.50View SEC Filing  
9/2/2014Mark PruzanskiCEOSell10,000$286.49$2,864,900.00View SEC Filing  
8/27/2014David ShapiroCMOSell10,000$293.93$2,939,300.00View SEC Filing  
8/26/2014Orbimed Advisors LlcDirectorSell111,258$298.06$33,161,559.48View SEC Filing  
8/25/2014Jonathan SilversteinDirectorSell50,000$295.59$14,779,500.00View SEC Filing  
8/15/2014David ShapiroCMOSell4,774$291.49$1,391,573.26View SEC Filing  
8/12/2014Daniel Paul ReganInsiderSell8,124$325.70$2,645,986.80View SEC Filing  
8/12/2014Klaus R Dr VeitingerDirectorSell316$345.62$109,215.92View SEC Filing  
8/1/2014Mark PruzanskiCEOSell10,000$226.72$2,267,200.00View SEC Filing  
7/10/2014Klaus R Dr VeitingerDirectorSell391$219.15$85,687.65View SEC Filing  
7/7/2014Lorenzo TallarigoDirectorSell2,000$243.06$486,120.00View SEC Filing  
7/2/2014David ShapiroCMOSell5,036$244.73$1,232,460.28View SEC Filing  
7/1/2014Mark PruzanskiCEOSell10,000$250.61$2,506,100.00View SEC Filing  
6/16/2014David ShapiroCMOSell4,000$278.15$1,112,600.00View SEC Filing  
6/2/2014Mark PruzanskiCEOSell10,000$230.60$2,306,000.00View SEC Filing  
5/9/2014Lorenzo TallarigoDirectorSell2,007$254.68$511,142.76View SEC Filing  
5/1/2014Mark PruzanskiCEOSell10,000$263.17$2,631,700.00View SEC Filing  
4/16/2014Mark PruzanskiCEOSell10,000$242.22$2,422,200.00View SEC Filing  
4/14/2014Barbara Gayle DuncanCFOSell1,154$279.00$321,966.00View SEC Filing  
4/10/2014Lorenzo TallarigoDirectorSell349,318$317.71$110,981,821.78View SEC Filing  
4/9/2014Orbimed Advisors LlcDirectorSell81,305$320.00$26,017,600.00View SEC Filing  
4/7/2014Luciano AdoriniInsiderSell2,000$283.90$567,800.00View SEC Filing  
4/2/2014David ShapiroCMOSell5,393$331.83$1,789,559.19View SEC Filing  
3/17/2014David ShapiroCMOSell4,456$437.49$1,949,455.44View SEC Filing  
2/14/2014Paolo FundaroDirectorSell7,246$375.26$2,719,133.96View SEC Filing  
1/16/2014Mark PruzanskiCEOSell10,000$273.68$2,736,800.00View SEC Filing  
1/16/2014Srinivas AkkarajuDirectorSell3,250$267.94$870,805.00View SEC Filing  
1/8/2014David ShapiroCMOSell4,928$71.85$354,076.80View SEC Filing  
1/7/2014Lorenzo TallarigoDirectorSell1,839$67.41$123,966.99View SEC Filing  
1/7/2014Luciano AdoriniInsiderSell1,634$67.41$110,147.94View SEC Filing  
12/16/2013David ShapiroCMOSell5,016$62.11$311,543.76View SEC Filing  
10/21/2013Francesco MicheliMajor ShareholderSell124,912$62.50$7,807,000.00View SEC Filing  
10/21/2013Jonathan SilversteinDirectorSell40,088$62.50$2,505,500.00View SEC Filing  
10/21/2013Luciano AdoriniInsiderSell2,000$55.51$111,020.00View SEC Filing  
10/15/2013Francesco MicheliMajor ShareholderSell1,123,415$62.50$70,213,437.50View SEC Filing  
10/15/2013Orbimed Advisors LlcDirectorSell376,585$62.50$23,536,562.50View SEC Filing  
10/2/2013David ShapiroCMOSell4,392$72.80$319,737.60View SEC Filing  
9/20/2013Luciano AdoriniInsiderSell2,000$61.07$122,140.00View SEC Filing  
9/17/2013Mark PruzanskiCEOSell25,000$52.00$1,300,000.00View SEC Filing  
9/13/2013Mark PruzanskiCEOSell12,500$49.02$612,750.00View SEC Filing  
8/20/2013Luciano AdoriniInsiderSell2,000$44.18$88,360.00View SEC Filing  
8/16/2013David ShapiroCMOSell5,016$49.20$246,787.20View SEC Filing  
8/15/2013David ShapiroCMOSell4,754$45.04$214,120.16View SEC Filing  
8/12/2013Mark PruzanskiCEOSell12,500$45.98$574,750.00View SEC Filing  
8/12/2013Paolo FundaroDirectorSell4,759$46.13$219,532.67View SEC Filing  
7/22/2013Luciano AdoriniInsiderSell2,000$49.44$98,880.00View SEC Filing  
7/15/2013Mark PruzanskiCEOSell25,000$50.05$1,251,250.00View SEC Filing  
7/9/2013Mark PruzanskiCEOSell37,500$46.36$1,738,500.00View SEC Filing  
7/8/2013Barbara Gayle DuncanCFOSell25,000$45.39$1,134,750.00View SEC Filing  
7/2/2013David ShapiroCMOSell4,369$43.63$190,619.47View SEC Filing  
6/26/2013Mark PruzanskiCEOSell12,500$40.06$500,750.00View SEC Filing  
6/20/2013Luciano AdoriniInsiderSell2,000$37.07$74,140.00View SEC Filing  
6/20/2013Mark PruzanskiCEOSell25,000$38.25$956,250.00View SEC Filing  
6/19/2013Barbara Gayle DuncanCFOSell50,575$34.50$1,744,837.50View SEC Filing  
6/17/2013David ShapiroCMOSell5,016$32.72$164,123.52View SEC Filing  
5/28/2013Barbara Gayle DuncanCFOSell6,225$34.50$214,762.50View SEC Filing  
5/20/2013Barbara Gayle DuncanCFOSell28,200$34.50$972,900.00View SEC Filing  
5/16/2013David ShapiroCMOSell5,016$31.31$157,050.96View SEC Filing  
4/9/2013David ShapiroCMOSell3,750$34.41$129,037.50View SEC Filing  
10/16/2012Jonathan SilversteinDirectorBuy333,334$15.00$5,000,010.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Intercept Pharmaceuticals (NASDAQ:ICPT)
Latest Headlines for Intercept Pharmaceuticals (NASDAQ:ICPT)
DateHeadline logo3 Growth Stocks That Could Soar More Than Dollar Tree - July 26 at 4:12 PM logoIntercept to Report Second Quarter 2017 Financial Results on July 31 - July 26 at 7:49 AM logoCan Intercept (ICPT) Beat Estimates this Earnings Season? - July 25 at 8:01 PM logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Given Consensus Rating of "Buy" by Analysts - July 24 at 10:16 AM logoDaniel G. Welch Sells 217 Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock - July 22 at 7:22 AM logoThe Best Stock in New York: Intercept Pharmaceuticals - July 21 at 4:15 PM logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) SVP Richard J. Kim Sells 89 Shares - July 18 at 10:28 PM logoBidaskClub Upgrades Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) to "Buy" - July 16 at 2:06 PM logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) CMO Sells $68,577.53 in Stock - July 13 at 10:52 PM logoBrokers Offer Predictions for Intercept Pharmaceuticals, Inc.'s Q2 2017 Earnings (NASDAQ:ICPT) - July 13 at 8:29 AM logoZacks: Analysts Expect Intercept Pharmaceuticals, Inc. (ICPT) Will Announce Quarterly Sales of $26.70 Million - July 12 at 9:51 AM logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock Rating Upgraded by Zacks Investment Research - July 11 at 4:52 PM logoZacks: Analysts Expect Intercept Pharmaceuticals, Inc. (ICPT) to Announce -$3.66 EPS - July 10 at 6:22 PM logoIntercept Pharmaceuticals, Inc. (ICPT) Earns Buy Rating from Analysts at Jefferies Group LLC - July 10 at 5:26 PM logoNoteworthy Friday Option Activity: CENX, ICPT, CACC - Nasdaq - July 9 at 8:35 AM logoCommit To Purchase Intercept Pharmaceuticals At $95, Earn 10.7% Annualized Using Options - July 7 at 6:22 AM logoMillions of people are living with a 'silent' disease they've likely never heard of - July 7 at 6:22 AM logoIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Insider Sells $47,804.02 in Stock - July 5 at 10:44 PM logoIntercept Pharmaceuticals, Inc. (ICPT) CMO David Shapiro Sells 350 Shares - July 5 at 10:44 PM logoSandip Kapadia Sells 1,431 Shares of Intercept Pharmaceuticals, Inc. (ICPT) Stock - July 5 at 10:22 PM logoMark Pruzanski Sells 1,434 Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Stock - July 5 at 10:22 PM logoBidaskClub Downgrades Intercept Pharmaceuticals, Inc. (ICPT) to Hold - July 5 at 8:38 PM logoNotable Two Hundred Day Moving Average Cross - ICPT - July 3 at 7:14 PM logoInsider Selling: Intercept Pharmaceuticals, Inc. (ICPT) CEO Sells 40,000 Shares of Stock - June 28 at 10:20 PM logoIntercept Pharmaceuticals, Inc. (ICPT) Receives Consensus Recommendation of "Hold" from Analysts - June 27 at 8:44 AM logoIntercept Pharmaceuticals, Inc. to Post FY2018 Earnings of ($15.37) Per Share, Cantor Fitzgerald Forecasts (ICPT) - June 26 at 8:54 AM logo[$$] One of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a Cure - June 23 at 11:09 PM logoIntercept Pharmaceuticals, Inc. (ICPT) Upgraded to "Buy" by BidaskClub - June 23 at 8:20 PM logoIntercept Pharmaceuticals, Inc. (ICPT) Stock Rating Reaffirmed by Wedbush - June 23 at 11:35 AM logoIntercept’s Ocaliva® (obeticholic acid) Receives 2017 Galien Chemical Synthesis Drug Award in Italy - June 22 at 1:19 PM logoNoteworthy Monday Option Activity: ICPT, EMN, C - Nasdaq - June 19 at 9:50 PM logoIntercept Pharmaceuticals, Inc. (ICPT) Expected to Announce Quarterly Sales of $26.70 Million - June 16 at 3:06 PM logoWedbush Brokers Boost Earnings Estimates for Intercept Pharmaceuticals, Inc. (ICPT) - June 15 at 8:06 AM logoZacks: Analysts Expect Intercept Pharmaceuticals, Inc. (ICPT) to Announce -$3.70 Earnings Per Share - June 14 at 4:26 PM logoIntercept Pharma (ICPT) Announces New Data Analysis From FLINT Trial of OCA in NASH Patients with Type 2 Diabetes - - June 13 at 5:36 PM logoIntercept (ICPT) Releases Data from Phase II Flint Trial - June 13 at 11:01 AM logoIntercept Pharmaceuticals, Inc. (ICPT) Given "Ourperform" Rating at Wedbush - June 13 at 8:28 AM logoIntercept Pharma (ICPT) Announces New Data Analysis From FLINT Trial of OCA in NASH Patients with Type 2 Diabetes - June 12 at 6:27 PM logoIntercept (ICPT) Down 3.5% Since Earnings Report: Can It Rebound? - June 12 at 6:27 PM logoIntercept Announces New Data Analysis From FLINT Trial of OCA in NASH Patients with Type 2 Diabetes - June 12 at 6:27 PM logoCowen and Company Reiterates Buy Rating for Intercept Pharmaceuticals, Inc. (ICPT) - June 12 at 4:20 PM logoETFs with exposure to Intercept Pharmaceuticals, Inc. : June 5, 2017 - June 5 at 5:53 PM logoToday's Research Reports on Stocks to Watch: Rite Aid and Intercept Pharmaceuticals - June 5 at 10:23 AM logoIntercept Pharmaceuticals (ICPT) Looks Good: Stock Adds 5.3% in Session - June 5 at 10:23 AM logoIntercept Pharmaceuticals Inc (ICPT) Given a $201.00 Price Target by Credit Suisse Group AG Analysts - June 4 at 11:46 PM logoIntercept Pharmaceuticals Inc (ICPT) Upgraded by ValuEngine to Sell - June 4 at 11:14 AM logoIntercept Pharmaceuticals Inc (ICPT) Insider Lisa Bright Sells 698 Shares - June 2 at 10:33 PM logoIntercept Pharmaceuticals Inc (ICPT) Given Average Rating of "Buy" by Analysts - May 31 at 7:54 AM logoInsider Selling: Intercept Pharmaceuticals Inc (ICPT) Insider Sells 254 Shares of Stock - May 30 at 10:40 PM logoIntercept's (ICPT) Liver Drug Ocaliva Approved in Canada - May 29 at 5:35 PM



Intercept Pharmaceuticals (ICPT) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by Staff